Tagged with ase

Japan Japan was once a global leader in life sciences innovation, introducing about a third of the world’s new drugs in the 1980s, but this positioning slipped following decades of economic stagnation compounded by a conservative regulatory regime. However recent regulatory reforms have brought a more positive outlook and sparked a…

Mexico Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example, often face delayed diagnoses, limited treatment options, and a lack of specialised care compared to those suffering from more common…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

China There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take on an increased significance, something that Chinese policymakers have worked to address in recent years.   “China now introduces new…

Switzerland Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF 7.3 billion (EUR 7.8 billion) with capital investments surpassing CHF 2 billion. While funding inflows still did not reach the…

China Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR, CARE, and RARE” focus with China’s evolving healthcare priorities, highlighting efforts to bring innovation through local and global collaborations, including…

USA Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four products approved across five indications, a blockbuster therapy that reached 2023 revenues of USD 328 million, and six candidates in…

Mexico Nicolas Linares of Ultragenyx Pharmaceutical Mexico highlights the company’s commitment to developing innovative treatments for rare and ultra-rare diseases. He emphasizes the importance of collaboration with healthcare systems and the need for a focused approach to address the unique challenges faced by patients in Mexico.   By fostering collaboration among…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…

Switzerland Christof Kloepper delves into the Basel Area’s positioning as a leading hub for life sciences and biotech innovation. Kloepper emphasizes the region’s commitment to attracting global companies, nurturing startups, and building a strong ecosystem of talent, research, and infrastructure. He draws a comparison to Boston and highlights the Basel Area’s…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Mexico David López García, a pharma industry executive and rare disease expert, discusses the challenges and advancements in treating rare diseases in Mexico. He highlights the importance of public-private partnerships and the growing interest from industry in the rare disease field.   Every day is an opportunity to make a difference…